4337-60-4

Basic information

• Product Name: Isothiazolo[5,4-b]pyridin-3-ol
• Synonyms: Isothiazolo[5,4-b]pyridin-3-ol;Isothiazolo[5,4-b]pyridin-3(2H)-one
• CAS NO: 4337-60-4
• Molecular Formula: C₆H₄N₂OS
• Molecular Weight: 152.17376
• Mol File: 4337-60-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Isothiazolo[5,4-b]pyridin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: Isothiazolo[5,4-b]pyridin-3-ol(4337-60-4)
• EPA Substance Registry System: Isothiazolo[5,4-b]pyridin-3-ol(4337-60-4)

Safety Data

• Hazardous Substances Data: 4337-60-4(Hazardous Substances Data)

Upstream product

• 121050-19-9 2-mercapto-N,N-dimethylnicotinamide 
• 38521-46-9 3-carboxy-2-mercaptopyridine 
• 50596-67-3 2-mercapto-3-pyridinecarboxamide 
• 97936-36-2 1,2-dihydro-2-thioxo-3-pyridinecarbonyl chloride 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 52505-45-0 2-mercaptopyridine-3-carbonitrile 
• 27916-10-5 2,2'-dithiobis(3-pyridinecarboxylic acid) 
• 117106-56-6 2,2'-dithiobis(ethyl 3-pyridinecarboxylate) 
• 117088-89-8 2,2'-trithiobis(3-pyridinecarboxylic acid) 
• 104857-34-3 2,2'-dithiobis(3-pyridinecarbonyl chloride) 
• 38521-46-9 1,2-dihydro-2-thioxo-3-pyridine carboxylic scid 
• 117088-90-1 2,2'-trithiobis(3-pyridinecarbonyl chloride) 

Downstream Products

• 91859-66-4 2-benzylisothiazolo<5,4-b>pyridin-3(2H)-one 
• 1314242-65-3 2-(4-methylbenzyl)isothiazolo[5,4-b]pyridin-3(2H)-one 
• 65282-46-4 2-(p-chlorobenzyl)isothiazolo<5,4-b>pyridin-3-one 
• 1314242-63-1 2-(4-fluorobenzyl)isothiazolo[5,4-b]pyridin-3(2H)-one 
• 168334-36-9 2-(3-methoxybenzyl)isothiazolo[5,4-b]pyridin-3(2H)-one 
• 168334-34-7 2-(4-(trifluoromethyl)benzyl)isothiazolo[5,4-b]pyridin-3(2H)-one 
• 1314242-64-2 2-(3,4-difluorobenzyl)isothiazolo[5,4-b]pyridin-3(2H)-one 
• 1314242-74-4 2-(3,4-dichlorobenzyl)-1-oxoisothiazolo[5,4-b]pyridin-3(2H)-one 
• 1314242-75-5 2-(3,4-dichlorobenzyl)-1,1-dioxoisothiazolo[5,4-b]pyridin-3(2H)-one 
• 1352432-95-1 N-[3-(furan-2-ylmethoxymethyl)benzyl]-3-oxo-3H-isothiazolo[5,4-b]pyridine-2-carboxamide 

Relevant articles and documents

NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF

The present disclosure provides, inter alia, compounds and compositions having the formula (I) as defined herein. Methods of using and making such compounds and compositions are also provided. The present disclosure further provides screening methods, including detectable probes as well as diagnostic methods and methods for monitoring the progress of a disease, such as a neurodegenerative disease.

Isothiazolinone compound and corresponding application

The invention provides an isothiazolinone compound with an IDO inhibitory activity, and a preparing method and pharmaceutical application thereof. The invention particularly relates to a compound shown in a formula I, pharmaceutically acceptable salts thereof, isomers and prodrugs, wherein definitions of all groups are shown in the description. The invention further relates to compound drug preparations, drug compositions and the application of the compound drug preparations and the drug compositions in treating, relieving and/or preventing various relevant diseases caused by immunosuppressionsuch as tumors, virus infection or autoimmune diseases. The isothiazolinone compound has the excellent IDO inhibitory activity.

Chemical Inhibition of Human Thymidylate Kinase and Structural Insights into the Phosphate Binding Loop and Ligand-Induced Degradation

Targeting thymidylate kinase (TMPK) that catalyzes the phosphotransfer reaction for formation of dTDP from dTMP is a new strategy for anticancer treatment. This study is to understand the inhibitory mechanism of a previously identified human TMPK (hTMPK) inhibitor YMU1 (1a) by molecular docking, isothermal titration calorimetry, and photoaffinity labeling. The molecular dynamics simulation suggests that 1a prefers binding at the catalytic site of hTMPK, whereas the hTMPK inhibitors that bear pyridino[d]isothiazolone or benzo[d]isothiazolone core structure in lieu of the dimethylpyridine-fused isothiazolone moiety in 1a can have access to both the ATP-binding and catalytic sites. The binding sites of hTMPK inhibitors were validated by photoaffinity labeling and mass spectrometric studies. Taking together, 1a and its analogues stabilize the conformation of ligand-induced degradation (LID) region of hTMPK and block the catalytic site or ATP-binding site, thus attenuating the ATP binding-induced closed conformation that is required for phosphorylation of dTMP.

ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS

The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES

The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.

Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors

We present a combination of database screening, synthesis and in vitro testing to identify novel histone acetyltransferase (HAT) inhibitors. The National Cancer Institute compound collection (NCI) and several commercial databases were filtered by similarity-based virtual screening to find new HAT inhibitors. Employing the recombinant HAT p300/CBP-associated factor (PCAF) and two different histone substrates for screening, pyridoisothiazolones were identified as inhibitors of human PCAF. Due to the limited solubility of the initial hits, we synthesized and tested them on PCAF. The compounds inhibit the proliferation of cancer cells. In summary, valuable chemical tools and potential lead candidates for new anticancer agents directed against HATs as new targets have been identified.

Urease inhibitors

A urease inhibitor and an anti-Helicobacter pylori agent, which contain, as an active ingredient, an isothiazole derivative represented by the general formula (1): wherein R1 represents a hydrogen atom or an amino group, R2 represents a hydrogen atom, a lower alkyl group, or an acetyl group, and X represents a carbon atom or a nitrogen atom. These drugs are effective to prevent and treat gastrointestinal diseases caused by urease of Helicobacter pylori, such as chronic gastritis and gastroduodenal ulcer.

Convenient synthesis of 1,2-benzisothiazol-3(2H)-ones by cyclization reaction of acyl azide

1,2-Benzisothiazol-3(2H)-one was synthesized by treatment of 2-mercaptobenzoic acid with diphenyl phosphoryl azide, followed by cyclization of the resulting acyl azide at low temperature, where Curtius rearrangement did not occur. 5-Amino-1,2-benzisothiazol-3(2H)-one was similarly synthesized in one pot from 4-mercaptoisophthalic acid.

N-unsubstituted sulfenamides by electrophilic amination of mercapto compounds

Potential mercapto compounds derived from electron deficient heterocycles as 2- and 4-thiouracils, pyridines and pyridine-1-oxide are animated by the oxaziridine 1 to new sulfenamides (6, 9, 11 and 15 or the isothiazolo-pyridine 14) which add to phenylisocyanates forming sulfenylureas (7, 10, 12 and 16). Several other mercapto compounds gave disulfides. Attempts of oxidation of the sulfenamides and the sulfenylureas were unsuccessful. The methylmercapto compound 19 after amination was hydrolyzed to the sulfoxide 20. Johann Ambrosius Barth 1997.